Mironid Secures £34M for ADPKD Breakthrough | Glasgow News

Glasgow’s Mironid just landed £34 million to revolutionize treatment for ADPKD, a devastating hereditary kidney disease affecting 12 million globally—with half facing kidney failure by 60. Backed by the Scottish National Investment Bank and big names like Roche and Sofinnova, this funding accelerates clinical development of groundbreaking therapies, spotlighting Scotland’s rising biotech power and its mission to turn science into life-saving impact. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9ce2c9aa07fb85fe